EUVIMEDEUVIMED entdecken
Crossref

Discovery and Preclinical Evaluation of PBX-7016, a Methylenedioxy-Camptothecin Payload for Antibody-Drug Conjugates with Enhanced Therapeutic Potential

Younghwa Chun, Byeong Sung Lee, Sohui Kweon, Hyemin Han, Seunggun Shin, Jaehyun Lee, Woogyum Kim, Jinhwan Cho, Byounggyu Yoo, Joonsun Yoon, Sungjae Yang, Doo Young Jung und 1 weitere

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.5c02706 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Younghwa Chun und 12 weiteren Autor:innen. Beteiligte Einrichtung: Pinotbio Inc., 156 Gwanggyo-ro, Youngtong-gu, Suwon, Gyeonggi-do 16506, South Korea. Hauptthemen laut MEDLINE: Camptothecin, Immunoconjugates, Antineoplastic Agents, Drug Discovery. Die Arbeit nennt 79 Literaturangaben. Gefördert von: Pinotbio Inc., Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Camptothecin derivatives have become cornerstone payloads in antibody-drug conjugates (ADCs), with recent clinical success driving continued optimization to improve therapeutic efficacy and safety. Herein, we present the development of PBX-7016 (14), a novel methylenedioxy-camptothecin analog. Hybrid molecules combining FL118 and Exatecan pharmacophores were synthesized and tested in vitro, yielding three lead compounds characterized by dual Topo1 inhibition and antiapoptotic protein suppression. Functional evaluation of ADC constructs incorporating these payloads validated physicochemical compatibility with antibody conjugation, target-dependent cytotoxicity, and antibody-like pharmacokinetics. When benchmarked against Enhertu, these ADCs showed superior bystander killing and in vivo efficacy across multiple xenograft models. Furthermore, PBX-7016-based ADCs maintained strong efficacy against various tumor-associated antigens, demonstrating therapeutic versatility. Notably, in vitro ADME profiling and rodent toxicology studies confirmed a favorable safety profile and good tolerability. PBX-7016 represents a differentiated camptothecin payload with strong translational promise, and its ADCs are currently advancing through Phase I trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CamptothecinImmunoconjugatesAntineoplastic AgentsDrug DiscoveryHumansAnimalsMiceCell Line, TumorXenograft Model Antitumor AssaysStructure-Activity RelationshipRatsTopoisomerase I InhibitorsFemale

Substanzen

CamptothecinImmunoconjugatesAntineoplastic AgentsTopoisomerase I Inhibitors

Autor:innen und Institutionen

  • Pinotbio Inc., 156 Gwanggyo-ro, Youngtong-gu, Suwon, Gyeonggi-do 16506, South Korea.
  • Celltrion Inc., 23 Academy-ro, Yeonsu-gu, Incheon 22014, South Korea.

ORCID-Profile: Gangadhar Rao Mathi

Förderung

  • Pinotbio Inc., Korea

Zitieren

APA

Chun, Y., Lee, B. S., Kweon, S., Han, H., Shin, S., Lee, J., Kim, W., Cho, J., Yoo, B., Yoon, J., Yang, S., Jung, D. Y., & Mathi, G. R. (2025). Discovery and Preclinical Evaluation of PBX-7016, a Methylenedioxy-Camptothecin Payload for Antibody-Drug Conjugates with Enhanced Therapeutic Potential. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02706

Vancouver

Chun Y, Lee BS, Kweon S, Han H, Shin S, Lee J, et al. Discovery and Preclinical Evaluation of PBX-7016, a Methylenedioxy-Camptothecin Payload for Antibody-Drug Conjugates with Enhanced Therapeutic Potential. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c02706

BibTeX
@article{Chun2025,
  author = {Chun, Younghwa and Lee, Byeong Sung and Kweon, Sohui and Han, Hyemin and Shin, Seunggun and Lee, Jaehyun and Kim, Woogyum and Cho, Jinhwan and Yoo, Byounggyu and Yoon, Joonsun and Yang, Sungjae and Jung, Doo Young and Mathi, Gangadhar Rao},
  title = {Discovery and Preclinical Evaluation of PBX-7016, a Methylenedioxy-Camptothecin Payload for Antibody-Drug Conjugates with Enhanced Therapeutic Potential},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.5c02706}
}
Kostenlos starten →